Physician profile
Scott M Jackson
NPI 1336267509
$532,964.82
in general payments reported to CMS, 2019-2025
27 companies · $185K in 2025
The $185K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.99 · 2020: $38.14 · 2021: $451 · 2022: $73K · 2023: $118K · 2024: $156K · 2025: $185K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $392K · Travel and Lodging: $29K · Consulting Fee: $25K · Food and Beverage: $13K · Education: $439 · Honoraria: $30.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $392,207.00 |
| Travel and Lodging | $29,280.76 |
| Consulting Fee | $24,952.00 |
| Food and Beverage | $12,517.19 |
| Education | $439.43 |
| Honoraria | $30.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $167,680.57 | 2021-2025 | Ebglyss, Olumiant, Taltz |
| Janssen Biotech, INC. | $157,859.29 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $102,263.60 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $60,037.14 | 2022-2024 | Tremfya |
| Galderma Laboratories, L.P. | $18,910.59 | 2024-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $18,052.57 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $3,367.63 | 2021-2025 | Cosentyx |
| Kyowa Kirin, INC. | $2,201.27 | 2021-2023 | Poteligeo |
| Sun Pharmaceutical Industries INC. | $453.96 | 2022-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $292.07 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $290.12 | 2020-2025 | Adbry, Anzupgo, Spevigo |
| Dermavant Sciences, INC. | $259.02 | 2022-2024 | Vtama |
| Amgen INC. | $219.03 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $209.06 | 2023-2024 | Sotyktu |
| Organon LLC | $154.92 | 2025 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $151.36 | 2021-2025 | Bimzelx |
| Kerecis Limited | $112.42 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Arcutis Biotherapeutics, INC. | $93.65 | 2024-2025 | Zoryve |
| Organogenesis INC. | $75.56 | 2024-2025 | Novachor, Cygnus Dual |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $55.04 | 2023 | Siliq |
| Pfizer INC. | $53.42 | 2021-2025 | |
| Biofrontera INC. | $39.28 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.61 | 2023-2024 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $27.31 | 2020-2022 | |
| Genentech USA, INC. | $24.70 | 2021-2022 | |
| Krystal Biotech INC | $23.25 | 2023 | Vyjuvek |
| Incyte Corporation | $22.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.